French Biotech Abivax's Shares Climb 11% on Eli Lilly Bid Rumors. Shares Have Gained 1765% YTD

Reuters12-10

Dec 10 (Reuters) - French biotech company Abivax's shares jumped by 11% on Wednesday on market rumours that U.S. pharma giant Eli Lilly might be interested in bidding for the business.

The "share price movement is driven by speculation around a possible takeover," said Damien Choplain, analyst at Stifel.

Abivax and Eli Lilly did not respond to initial requests for comment.

The French company announced in July positive results from a Phase 3 trial of its key drug obefazimod for the treatment of ulcerative colitis, sending its Paris-listed shares soaring over 500% in a day, and filed for an offering of up to $400 millions in American Depositary Shares.

By 1007 GMT on Wednesday, the stock was on track for an 18-fold increase in value since the beginning of the year, having reached a market valuation of over 8 billion euros ($9.3 billion), up from just 500 million euros in January.

($1 = 0.8595 euros)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment